OTUD7A

OTUD7A is an OTU-family deubiquitinase that employs a Cys210/His367 catalytic dyad with selectivity for Lys11-linked polyubiquitin chains, stabilizing diverse substrates—including Ankyrin-G, TAK1, EWS-FLI1, TRAF6, and KDM5B—by opposing their ubiquitin-dependent proteasomal degradation (PMID:39782030, PMID:34060252, PMID:36604605, PMID:41268652). In cortical neurons, OTUD7A localizes to dendritic spines and the axon initial segment, where it deubiquitinates and maintains Ankyrin-G levels; loss of OTUD7A reduces dendritic spine density, decreases glutamatergic synaptic transmission, and disrupts neuronal network activity, establishing it as a critical regulator of excitatory synapse structure and function (PMID:29395075, PMID:36604605, PMID:35931052). Loss-of-function mutations in OTUD7A, including the catalytic-domain variant p.Leu233Phe and haploinsufficiency from 15q13.3 microdeletions, cause neurodevelopmental phenotypes including epilepsy and intellectual disability (PMID:29395074, PMID:31997314, PMID:36604605). Outside the nervous system, OTUD7A stabilizes TAK1 to promote JNK/P38 signaling in pathological cardiac hypertrophy and stabilizes EWS-FLI1 to sustain Ewing sarcoma growth (PMID:41268652, PMID:34060252).

1. 2013 Medium

   The initial mechanistic question—does OTUD7A function as a deubiquitinase with defined signaling targets?—was addressed by showing it interacts with TRAF6, removes its polyubiquitin chains, and thereby modulates NF-κB signaling.

   Evidence Co-immunoprecipitation, in vivo deubiquitination assay, and NF-κB reporter assay in cell lines

   PMID:23792447

   Open questions at the time

   • Single study without reciprocal validation of the TRAF6 interaction by orthogonal methods
   • Linkage-type specificity of deubiquitination not determined
   • In vivo physiological relevance not tested
2. 2018 High

   Whether OTUD7A has a physiological role in the nervous system was established by two independent studies showing it localizes to dendritic spines and is required for normal spine density, dendrite outgrowth, and glutamatergic synaptic transmission in the cortex, directly linking it to 15q13.3 microdeletion syndrome phenotypes.

   Evidence Heterozygous 15q13.3 deletion mouse model and Otud7a-knockout mice with immunofluorescence, spine morphometry, and mEPSC electrophysiology

   PMID:29395074 PMID:29395075

   Open questions at the time

   • Molecular substrates in neurons not yet identified
   • Whether the catalytic activity or a scaffolding role mediates the synaptic phenotype was unknown
   • Human neuronal validation not performed
3. 2020 Medium

   A human disease-causing mechanism was clarified when a homozygous p.Leu233Phe variant in the OTU catalytic domain was shown to impair proteasome complex formation and function, linking a specific catalytic-domain mutation to neurological disease.

   Evidence Trio exome sequencing, proteasome activity assays in patient fibroblasts and OTUD7A-knockout HAP1 cells

   PMID:31997314

   Open questions at the time

   • Single family; replication in additional patients needed
   • How a deubiquitinase mutation impairs the proteasome complex remains mechanistically unclear
   • Whether L233F abolishes deubiquitinase catalytic activity per se was not directly tested
4. 2021 High

   The question of whether OTUD7A stabilizes oncoproteins was answered by demonstrating it deubiquitinates and stabilizes EWS-FLI1, opposing SPOP-mediated degradation; OTUD7A depletion reduced EWS-FLI1 levels and suppressed Ewing sarcoma growth in vivo.

   Evidence Co-IP, in vivo deubiquitination assay, knockdown in Ewing sarcoma cell lines, xenograft model, catalytic inhibitor 7Ai

   PMID:34060252

   Open questions at the time

   • Whether 7Ai is specific to OTUD7A versus other OTU-family members not fully resolved
   • Structural basis of EWS-FLI1 recognition unknown
   • Linkage specificity for EWS-FLI1 deubiquitination not determined
5. 2022 Medium

   Translation to human neurons was achieved by showing that CRISPR-engineered OTUD7A loss-of-function in iPSC-derived neurons reduces dendritic complexity, synaptic protein levels (GluA1, PSD-95), and network activity, with transcriptomics confirming enrichment for synapse development pathways.

   Evidence CRISPR-Cas9 knockout in human iPSC-derived neurons, immunofluorescence, multi-electrode array, transcriptomic analysis

   PMID:35931052

   Open questions at the time

   • Single isogenic pair; additional clonal lines not reported
   • Direct OTUD7A substrates responsible for the transcriptomic changes not identified
   • Whether phenotypes are rescue-able by catalytic-active OTUD7A was not tested
6. 2023 High

   The critical neuronal substrate question was resolved by identifying Ankyrin-G and Ankyrin-B as direct OTUD7A interactors; OTUD7A prevents Ankyrin-G polyubiquitination and degradation at the axon initial segment and dendritic spine nanodomains, and the L233F epilepsy variant disrupts these interactions. Rescue of Ankyrin-G reversed neuronal deficits in 15q13.3 microdeletion neurons.

   Evidence BioID2 proximity-labeling proteomics, co-IP, structured illumination microscopy, polyubiquitination assays, patient iPSC-derived neurons with rescue experiments

   PMID:36604605

   Open questions at the time

   • Whether additional neuronal substrates contribute to the phenotype beyond Ankyrins is unknown
   • The ubiquitin linkage type on Ankyrin-G cleaved by OTUD7A was not determined
   • In vivo rescue in mouse models not performed
7. 2025 High

   A cardiac role was established: OTUD7A deubiquitinates and stabilizes TAK1, activating JNK/P38 signaling to drive pathological cardiac hypertrophy, as demonstrated by cardiac-specific knockout (protective) and overexpression (aggravating) with TAK1-dependent epistasis.

   Evidence Cardiac-specific Otud7a knockout and AAV9-mediated overexpression in mice, co-IP, ubiquitination assays, TAK1 inhibitor and overexpression epistasis

   PMID:41268652

   Open questions at the time

   • Whether OTUD7A regulation of TAK1 extends to inflammatory contexts beyond the heart is unknown
   • The ubiquitin ligase opposing OTUD7A on TAK1 was not identified
   • Whether the Lys11-linkage preference applies to TAK1 deubiquitination specifically was not tested
8. 2025 Medium

   The catalytic mechanism was elucidated at atomic resolution: OTUD7A uses a Cys210/His367 dyad (not a classical catalytic triad), with His367 polarized through a water bridge to Glu173 and an oxyanion hole in the C-loop, selectively cleaving Lys11-linked polyubiquitin via a tetrahedral intermediate.

   Evidence 12 µs molecular dynamics simulations and QM/MM calculations on the diubiquitin–Cez2 complex

   PMID:39782030

   Open questions at the time

   • Computational predictions lack experimental mutagenesis validation
   • Whether the Lys11 selectivity mechanism applies to all substrates in cells is untested
   • Crystal structure of a substrate-bound OTUD7A complex not available
9. 2025 Medium

   An oncogenic substrate-stabilization role in lung cancer was demonstrated: OTUD7A stabilizes the histone demethylase KDM5B in KRAS-mutant lung adenocarcinoma, and its inhibition triggers H4K20me3 increase, GABPA downregulation, mitochondrial ROS accumulation, and ferroptosis.

   Evidence KRAS-mutant LUAD cell lines, mouse and organoid models, cisplatin combination treatment, pathway analysis

   PMID:41422226

   Open questions at the time

   • Direct biochemical deubiquitination assay for KDM5B by OTUD7A not shown
   • Whether OTUD7A inhibition sensitizes non-KRAS-mutant tumors is unknown
   • The ferroptosis pathway link requires independent replication

• Key unresolved questions include the full substrate repertoire of OTUD7A in neurons, whether its Lys11-linkage selectivity governs all physiological substrates, and the structural basis for substrate recognition.
• No crystal structure of full-length OTUD7A with a bound substrate
• Comprehensive substrate identification across tissues not performed
• Therapeutic window for OTUD7A inhibition in cancer versus neurological toxicity unexplored